PHIO News and Press, Phio Pharmaceuticals Corp. From 09/03/25

Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-762 5th cohort patients now being treated in on-going clinical study King of Prussia, Pennsylvania--(Newsfile Corp. - September 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-...

2025-08-15 06:40:52 ET More on Phio Pharmaceuticals Phio Pharmaceuticals stock jumps 24% on partnering with U.S. drug substance manufacturer Seeking Alpha’s Quant Rating on Phio Pharmaceuticals Historical earnings data for Phio Pharmaceuticals Financia...

2025-08-14 16:50:22 ET More on Phio Pharmaceuticals Phio Pharmaceuticals stock jumps 24% on partnering with U.S. drug substance manufacturer Seeking Alpha’s Quant Rating on Phio Pharmaceuticals Historical earnings data for Phio Pharmaceuticals Financia...

Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 5th cohort enrolling patients in on-going clinical study King of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company develo...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

Phio Pharmaceuticals Corp. (PHIO) is expected to report $-0.36 for Q2 2025

King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into d...

Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patient King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutica...

A look at the top 10 most actives in the United States Healthcare Triangle Inc. (HCTI) rose 43.6% to $0.078 on volume of 886,705,727 shares Garden Stage Limited (GSIW) rose 25.8% to $0.1371 on volume of 90,504,815 shares Mullen Automotive Inc. (MULN) fell 5.1% to $0.06075 on volume of 82,32...

2025-07-25 08:24:30 ET More on Phio Pharmaceuticals Seeking Alpha’s Quant Rating on Phio Pharmaceuticals Historical earnings data for Phio Pharmaceuticals Financial information for Phio Pharmaceuticals Read the full article on Seeking Alpha For...